Microfluidic Chip based direct triple antibody immunoassay for monitoring patient comparative response to leukemia treatment

İÇÖZ K., Akar U., ÜNAL E.

BIOMEDICAL MICRODEVICES, vol.22, no.3, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.1007/s10544-020-00503-6
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, Biotechnology Research Abstracts, CINAHL, Compendex, EMBASE, INSPEC, MEDLINE
  • Keywords: Magnetic micro, nano particles, Immunoassay, Biochip, Leukemia, Direct triple antibody, Microfluidic -based monitoring, comparative response, MINIMAL RESIDUAL DISEASE, ACUTE LYMPHOBLASTIC-LEUKEMIA, CELLS
  • Erciyes University Affiliated: Yes


We report a time and cost-efficient microfluidic chip for screening the leukemia cells having three specific antigens. In this method, the target blast cells are double sorted with immunomagnetic beads and captured by the 3rd antibody immobilized on the gold surface in a microfluidic chip. The captured blast cells in the chip were imaged using a bright-field optical microscope and images were analyzed to quantify the cells. First sorting was performed with nano size immunomagnetic beads and followed by 2nd sorting where micron size immunomagnetic beads were used. The low-cost microfluidic platform is made of PMMA and glass including micro size gold pads. The developed microfluidic platform was optimized with cultured B type lymphoblast cells and tested with the samples of leukemia patients. The 8 bone marrow samples of 4 leukemia patients on the initial diagnosis and on the 15th day after the start of the chemotherapy treatment were tested both with the developed microfluidic platform and the flow cytometry. A 99% statistical agreement between the two methods shows that the microfluidic chip is able to monitor the decrease in the number of blast cells due to the chemotherapy. The experiments with the patient samples demonstrate that the developed system can perform relative measurements and have a potential to monitor the patient response to the applied therapy and to enable personalized dose adjustment.